Literature DB >> 8637235

Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells.

U Dehmel1, M Zaborski, G Meierhoff, O Rosnet, D Birnbaum, W D Ludwig, H Quentmeier, H G Drexler.   

Abstract

The growth of cells in vitro and in vivo is regulated by several environmental signals among which growth factors (cytokines) figure prominently. FLT3 is a novel cytokine receptor with intrinsic ligand-stimulated (FLT3 ligand, FL) tyrosine kinase activity. Here, using a specific anti-FLT3 monoclonal antibody (McAb) and flow cytometry we determined the expression pattern of the receptor protein in 55 human leukemia-lymphoma cell lines and in 20 primary samples from patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). FLT3 receptor surface expression was found predominantly in pre-B cell, myeloid and monocytic cell lines and in pre-B-ALL and AML cells, FL was overexpressed in baby hamster kidney cells producing a recombinant protein that was functional in receptor binding and signaling. Incubation with FL induced 3H-thymidine uptake-measured proliferation in some myeloid cell lines and in 2/9 AML cases. The strongest proliferative response was seen in the two growth factor-dependent myeloid leukemia cell lines MUTZ-2 and OCI-AML-5. Long-term substitution of the commonly used cytokines with FL sustained the continuous proliferation of these two cell lines suggesting that also upon permanent activation FLT2 can function as a mitogenic signaling molecule. Despite the high density of FLT3 receptor expression on cultured and fresh pre-B-ALL cells, no proliferation could be stimulated in any of these specimens. Incubation with the anti-FLT3 McAb had agonistic proliferative effects in MUTZ-2 and OCI-AML-5; and anti-FL reagent blocked FL-stimulated proliferation. To summarize, we demonstrated that FL is effective in inducing proliferation of leukemic myeloid cells and that protein expression does not necessarily indicate an FL-responsive cell. While the present data clearly demonstrate that FL might play a proliferative role in leukemogenesis, further studies are needed to clarify whether the signals provided by FL:FLT3 interaction are confined to a proliferation-inducing function or whether maturational progression could also be elicited in certain cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637235

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  6 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Efficient production of bioactive recombinant human Flt3 ligand in E. coli.

Authors:  Kenneth Verstraete; Sina Koch; Sevgi Ertugrul; Isabel Vandenberghe; Maarten Aerts; Gonzalez Vandriessche; Christian Thiede; Savvas N Savvides
Journal:  Protein J       Date:  2009-02       Impact factor: 2.371

Review 4.  The Biology and Targeting of FLT3 in Pediatric Leukemia.

Authors:  Colleen E Annesley; Patrick Brown
Journal:  Front Oncol       Date:  2014-09-23       Impact factor: 6.244

Review 5.  FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION.

Authors:  Hitoshi Kiyoi
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

Review 6.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Jianbiao Zhou; Boon-Cher Goh; Daniel H Albert; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.